Funding

Sources of Funding, Updated January 2019

ICER’s mission is funded through a diverse combination of sources as grants, contracts and unrestricted gifts; funding is not accepted from manufacturers or private insurers to perform reviews of specific technologies. ICER’s core programs, CTAF, Midwest CEPAC, and New England CEPAC, receive their funding from private foundations.  Since June 2018, ICER has received funding from the following sources:

  • Apex Healthcare Consulting
  • Blue Cross Blue Shield of Massachusetts
  • Blue Shield of California Foundation
  • Boston University School of Public Health
  • California Health Care Foundation
  • Commonwealth Fund
  • Harvard Pilgrim Health Care
  • Jeffries
  • Laura and John Arnold Foundation
  • National Institute for Health Care Management
  • NESCSO/University of Massachusetts
  • Network for Good
  • Partners Healthcare
  • RBC Capital Markets
  • University of Colorado
ICER also receives support from pharmaceutical and health insurance companies for the annual ICER Policy Summit, Evidence Dialogue webinars, and other membership activities.  Current members include:

  • Aetna
  • Allergan
  • Alnylam Pharmaceuticals
  • America’s Health Insurance Plans (AHIP)
  • Anthem
  • AstraZeneca
  • Biogen
  • Blue Shield of California
  • Cambia Health Solutions and MedSavvy
  • CVS Caremark
  • Editas
  • Express Scripts
  • Genentech
  • GlaxoSmithKline
  • Harvard Pilgrim Health Care
  • Health Care Service Corporation (HCSC)
  • HealthPartners
  • Johnson & Johnson
  • Kaiser Permanente
  • LEO Pharma
  • Mallinckrodt Pharmaceuticals
  • Merck & Co.
  • National Pharmaceutical Council
  • Novartis
  • Premera Blue Cross
  • Prime Therapeutics
  • Regeneron
  • Sanofi
  • United HealthCare